Prosigna: Breast Cancer Stays on Track

In 2020, 2.3 million women worldwide have been diagnosed with breast cancer, with over 264,000 in the United States.

With spectacular advances made by cancer research, more than 3.8 million people in the United States and millions more worldwide are breast cancer survivors who are living with, through, and beyond their disease.

Breast cancer treatment often includes three components:

• Surgical removal of the tumor.
• Radiotherapy is being used to try to control the cancer in the breast, lymph nodes, and adjacent tissues.
• Oral or intravenous systemic therapy to treat and/or limit the danger of cancer spread.

siParadigm’s Prosigna is a test for determining the risk of recurrence of breast cancer in postmenopausal women. It is a gene expression-based test that evaluates the expression of 50 genes associated with breast cancer recurrence. The test looks at the expression levels of these genes to determine how likely it is that the patient will experience a recurrence of their cancer.

Prosigna has been used in more than 200,000 patients since its launch, which is more accurate than traditional clinical risk factors in predicting breast cancer recurrence. The test is used in conjunction with other risk factors to provide a more accurate assessment of an individual’s risk of recurrence.

siParadigm's Prosigna is set to revolutionize the way healthcare providers treat breast cancer. Don't settle for anything less than Prosigna.